U.S. markets closed

Flexion Therapeutics, Inc. (FLXN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.16-0.15 (-1.61%)
At close: 4:00PM EDT
9.16 0.00 (0.00%)
After hours: 05:52PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close9.31
Open9.20
Bid8.50 x 800
Ask9.42 x 900
Day's Range8.82 - 9.30
52 Week Range6.71 - 14.39
Volume2,103,247
Avg. Volume940,309
Market Cap457.47M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-2.20
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.15
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
    GlobeNewswire

    Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference

    BURLINGTON, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2021 Raymond James Human Health Innovation Conference. The virtual fireside chat is scheduled to begin at 3:20 p.m. ET on Monday, June 21, 2021. To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com. Abo

  • Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer
    GlobeNewswire

    Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer

    BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021. "Will brings an impressive combination of medical, clinical, regulatory and corporate development skills, complemented by deep commercial experience he gained launching seven products throughout his career,” said Michael Clayman, MD, President and Chief Executive Officer

  • Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    GlobeNewswire

    Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BURLINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of 8,510 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of June 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The restrict